196 related articles for article (PubMed ID: 22314405)
1. Current world literature.
Curr Opin HIV AIDS; 2012 Mar; 7(2):203-9. PubMed ID: 22314405
[No Abstract] [Full Text] [Related]
2. Using HIV viral load to guide treatment-for-prevention interventions.
Novitsky V; Essex M
Curr Opin HIV AIDS; 2012 Mar; 7(2):117-24. PubMed ID: 22258501
[TBL] [Abstract][Full Text] [Related]
3. [HIV eradication--facts and fiction].
Jaeger H; Wolf E
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():72-3. PubMed ID: 19024923
[No Abstract] [Full Text] [Related]
4. Status of anti-HIV-1 chemotherapy in Japan.
Oishi T; Sugiura W; Matsuda M; Abumi H; Okano A; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Yoshioka A; Kashiwagi S; Shirahata A; Nagai Y
Jpn J Infect Dis; 1999 Apr; 52(2):51-2. PubMed ID: 10817968
[No Abstract] [Full Text] [Related]
5. Dynamics and evolution of HIV-1 during structured treatment interruptions.
Frost SD
AIDS Rev; 2002; 4(3):119-27. PubMed ID: 12416446
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral resistance.
Geretti AM
J HIV Ther; 2006 Dec; 11(4):72-3. PubMed ID: 17578209
[No Abstract] [Full Text] [Related]
7. HIV therapeutics: points from the recent literature.
Laurence J
AIDS Read; 2003 Jul; 13(7):305, 307. PubMed ID: 12889448
[No Abstract] [Full Text] [Related]
8. 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February, San Francisco, CA. Treatment as prevention.
Cohen J
Science; 2010 Mar; 327(5970):1196-7. PubMed ID: 20203028
[No Abstract] [Full Text] [Related]
9. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
10. Changing transmission fitness of drug-resistant human immunodeficiency virus against a background of evolving antiretroviral therapy.
Murray JM
J Infect Dis; 2003 Oct; 188(8):1258; author reply 1258-9. PubMed ID: 14551898
[No Abstract] [Full Text] [Related]
11. [Highly active initial therapy without resistance development. Even after 6 years still effective HIV therapy].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():54-5. PubMed ID: 16385876
[No Abstract] [Full Text] [Related]
12. Use of antiretroviral drugs to prevent sexual transmission of HIV.
Cohen MS; Hosseinipour M; Kashuba A; Butera S
Curr Clin Top Infect Dis; 2002; 22():214-51. PubMed ID: 12520656
[No Abstract] [Full Text] [Related]
13. [Antiretroviral therapy in 2004].
Jablonowski H
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():46-8, 50-1. PubMed ID: 15373049
[TBL] [Abstract][Full Text] [Related]
14. How individual can personalized antiretroviral treatment be? Deep salvage in an HIV-1-infected patient.
Jensen B; Esser S; Kaiser R; Luebke N; Häussinger D
Intervirology; 2012; 55(2):167-71. PubMed ID: 22286888
[TBL] [Abstract][Full Text] [Related]
15. How reliable is an undetectable viral load?
Combescure C; Vallier N; Ledergerber B; Cavassini M; Furrer H; Rauch A; Battegay M; Bernasconi E; Vernazza P; Hirschel B;
HIV Med; 2009 Sep; 10(8):470-6. PubMed ID: 19459990
[TBL] [Abstract][Full Text] [Related]
16. Inadvertent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in dual HIV-1/2 and HIV-2 seropositive West Africans: a retrospective study.
Sarfo FS; Bibby DF; Schwab U; Appiah LT; Clark DA; Collini P; Phillips R; Green I; Dittmar MT; Chadwick DR
J Antimicrob Chemother; 2009 Sep; 64(3):667-9. PubMed ID: 19549668
[No Abstract] [Full Text] [Related]
17. Discordant movement of CD4-positive T-cell count in HIV-1 infected patients with HAART failure.
Okano A; Matsuda M; Chiba T; Moriya K; Yamada K; Sugiura W
Jpn J Infect Dis; 2002 Apr; 55(2):62-5. PubMed ID: 12082315
[No Abstract] [Full Text] [Related]
18. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
Grant PM; Zolopa AR
Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
[TBL] [Abstract][Full Text] [Related]
19. Two versus three-class antiretroviral therapy in antiretroviral-naive patients in different time periods of the HAART era.
Taffé P; Bucher HC; Flepp M; Battegay M
AIDS; 2007 Feb; 21(4):537-8. PubMed ID: 17301581
[No Abstract] [Full Text] [Related]
20. HIV-2 down, HIV-1 to go? Understanding the possibilities of treatment as prevention.
Bruhn CA; Gilbert MT
Lancet Infect Dis; 2011 Apr; 11(4):260-1. PubMed ID: 21453865
[No Abstract] [Full Text] [Related]
[Next] [New Search]
